Announcements

Meeting/Conference: Next Gen Immuno-Oncology Congress - 14 - 15 March 2017

 

Venue:

London - UK

Description:

Next Gen Immuno-Oncology Congress to be held on 14th and 15th March 2017  in London UK aims to bring academicians, researchers and scientist from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the growth of existing therapeutics and pave way for emerging next generation therapeutics. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced.

URL:

http://www.mnmconferences.com/Next-Gen-Immuno-Oncology-Congress

Contact Information:

Contact Person – Ajay Nimbalkar

Email: ajay.nimbalkar@mnmconferences.com

 
Posted: 2016-07-07 More...
 

Journal Announcement: New Impact Factor of 1.829 for Current Oncology!

 


We are pleased to announce to our readers that Current Oncology’s 2015 Impact Factor has increased to 1.829! This is an increase from our 2014 stats, where we received an impact factor of 1.785.

The journal impact factor is a measure of citation frequency that reflects the average number of citations to articles published in science and social science journals. Impact factors are calculated annually for those journals that are indexed in Thomson Reuters Journal Citation Reports. The impact factor of a journal in a given year is the average number of citations a paper published in that journal received during the two previous years. The impact factor is often used to rank the relative importance and scientific caliber of a journal within its field.

Our 2015 Impact Factor is a significant achievement for the journal, and demonstrates the increased recognition of Current Oncology in the field, and the improved relevance and quality of our articles. Thank you to our team of Editors and Section Editors, Reviewers and Authors for their valuable contribution to the journal. We look forward to continued success in 2016 as the journal continues to strengthen and grow!

Multimed Inc.
Publisher of Current Oncology

 
Posted: 2016-06-16 More...
 

Meeting/Conference: Atlantic Canada Oncology Group Annual CME, Halifax, June 18-19, 2016

 

ACOG will host our 20th annual education event in Halifax on Friday afternoon and Saturday morning, June 18-19. Registration includes a lobster dinner and social event on the waterfront Friday evening.

The meeting will focus on breast cancer and a variety of other topics. Details of the program and registration are posted at acog.ca, or email edsmith@nl.rogers.com.

 
Posted: 2016-04-04
 

Journal Announcement: Current Oncology, Vol 23, Suppl 2 - Now Published!

 

Use of Cannabinoids in Cancer Care

Multimed Inc. is pleased to announce that Current Oncology has published a supplement dedicated to the use of cannabinoids in cancer care.Edited by Dr. Mark Ware, this issue brings together the work of some of the leading minds around the world who have dedicated themselves and their laboratories to understanding the role of cannabis and cannabinoids in the pathophysiology and management of cancer. This collection of papers takes us on a journey from bedside to bench and back, and provides a series of important signposts that will help to chart a path to better cancer care.

We would like to thank all of the contributing authors for their work on this special supplement. We would also like to send a special thank you to Dr. Mark Ware for his hard work and dedication in bringing this supplement to fruition.

Publication of this supplement was made possible through an unrestricted grant from Mettrum to the Canadian Consortium for the Investigation of Cannabinoids (CCIC). We sincerely thank Mettrum for their support of this project and for their ongoing commitment to research and education in cannabinoid medicine.

To view the full Table of Contents, please click here.

 
Posted: 2016-03-24 More...
 

Journal Announcement: Current Oncology, Vol 23, Suppl 1 - Now Published!

 

Original Cancer Costing Research Using Canadian Data

Multimed Inc. is pleased to announce that Current Oncology has published a supplement dedicated to cancer costing research using Canadian data. Co-edited by Dr. Nicole Mittmann (Cancer Care Ontario, Toronto, ON) and Dr. Claire de Oliveira (Centre for Addiction and Mental Health, Toronto, ON), the manuscripts in this supplement use a wide array of methods and Canadian data sources to deal with various disease sites and relevant issues in cancer care. In particular, they include studies relating to breast cancer (analysis of the cost implications of unwarranted imaging of patients, and an economic evaluation of a novel technology) and cervical cancer (estimation of utilization and costs, and use of a simulation model to evaluate cytology compared with primary human papillomavirus dna screening). Other studies focus on the estimation of drug and pathology cost avoidance in clinical trials and the cost trajectories of cancer patients over time. Finally, two studies provide an overview of the trends in costs for systemic therapy, home nursing, and hospitalizations for end-of-life care across the country.

We would like to thank all of the contributing authors for their work on this special supplement. We would also like to send a special thank you to Dr. Nicole Mittmann and Dr. Claire de Oliveira for their hard work and dedication as well as the Canadian Partnership Against Cancer for their support.

To view the full Table of Contents, please click here.

 
Posted: 2016-03-02 More...
 

Call for Applications: Editor-in-Chief for Current Oncology

 
We are conducting a Canada-wide search for the position of Editor-in-Chief (EIC) for Current Oncology through a Call for Applications. The position will commence July 2016, with the first issue, Volume 24, #1 (February 2017), being published under the leadership of the EIC. The newly appointed EIC will work together with the Journal's Deputy Editor, Dr. Phil Gold and the Managing Editor, Dr. Martin Chasen. For further information about the role of the EIC, and the application process, please refer to the "Call for Applications". The application deadline is March 31st, 2016.

 
Posted: 2016-02-25 More...
 

New Journal Look – Launching April 2016

 

To stay in line with current trends, journal scope, and to set the next stage for the journal, we are developing a new look for Current Oncology. The new look will launch with our April 2016 issue. As a preview, we are pleased to unveil our new logo:


 
Posted: 2016-02-25 More...
 

Journal Announcement: New Impact Factor of 1.785 for Current Oncology!

 

We are pleased to announce to our readers that Current Oncology’s 2014 Impact Factor has increased to 1.785! This is an increase from our 2014 stats, where we received an impact factor of 1.643.

The journal impact factor is a measure of citation frequency that reflects the average number of citations to articles published in science and social science journals. Impact factors are calculated annually for those journals that are indexed in Thomson Reuters Journal Citation Reports. The impact factor of a journal in a given year is the average number of citations a paper published in that journal received during the two previous years. The impact factor is often used to rank the relative importance and scientific caliber of a journal within its field.

Our 2014 Impact Factor is a significant achievement for the journal, and demonstrates the increased recognition of Current Oncology in the field, and the improved relevance and quality of our articles. Thank you to our team of Editors and Section Editors, Reviewers and Authors for their valuable contribution to the journal. We look forward to continued success in 2015 as the journal continues to strengthen and grow!

Multimed Inc.
Publisher of Current Oncology

 
Posted: 2015-06-25 More...
 

Journal Announcement: Current Oncology, Vol 22, Suppl 1 - Now Published!

 
Updated Guidelines, Consensus and Evidence-Based Reports in Breast Cancer

Multimed Inc. is pleased to announce that Current Oncology has published a supplement dedicated to breast cancer, edited by Dr. Maureen Trudeau from the Sunnybrook Health Sciences Centre in Toronto, Ontario.

The supplement is comprised of the most recent adjuvant breast cancer guidelines completed for the Program in Evidence Based Care of Cancer Care Oncology (CCO).  Readers will be able to find up to date and evidence based guidelines and consensus documents all in one place.

The supplement also includes evidence based reviews or consensus recommendations on locally advanced breast cancer for both local/regional management and systemic treatment. A Canadian group of content experts have been working on appropriate algorithms for neoadjuvant treatment over the last few years and had just completed a set of recommendations which have been included in the supplement; and another CCO guideline on local/regional management of locally advanced disease was just completed as well.

A Canadian flair was added to summaries based on International guidelines already published by Canadian experts with special interest in the treatment of HER2+ and HER2- disease.

Lastly, a review of pregnancy related breast cancer -breast cancer during pregnancy or pregnancy after breast cancer -was included as a topic of special interest for the management of the many young women with breast cancer.

We would like to thank all of the contributing oncologists for their work on this special supplement. We would also like to send a special thank you to Dr. Maureen Trudeau for her hard work and dedication in creating this important tool for oncologists.

Click here to read the supplement.

 
Posted: 2015-03-23
 

Meeting/Conference: Join Canadian Oncology Pharmacists at CAPhO Conference 2015 in St. John’s, May 21 – 24, 2015

 

 

 

Register now to participate in this year's CAPhO Conference 2015 (CAPhO 2015), a leading edge annual educational event produced by the Canadian Association of Pharmacy in Oncology (CAPhO) that defines the practice of oncology pharmacy in Canada. CAPhO 2015 will be held May 21- 24, 2015 at the Delta St. John’s Hotel and Conference Centre.

The three-day program is an ensemble of satellite symposia, plenary sessions, breakout sessions and networking events. The theme of CAPhO 2015 is Change, Challenge and Opportunity.

Change: Personalized medicine with complex targeted therapies, innovative delivery models, and patient engagement have changed the way cancer is treated. 

Challenge: Significant advances in the treatment of cancer come at a turbulent time, as the population is aging, the incidence of cancer is on the rise and the costs of providing treatment are continually escalating. 

Opportunity: With change and challenge comes opportunity, particularly for oncology pharmacists.

If you are an oncology pharmacist, technician, pharmacy assistant and other health care professional interested in the practice of oncology pharmacy in Canada, register today to attend CAPhO 2015 and become a member of CAPhO.  Also sign up to receive the e-newsletter so that you stay informed.

 
Posted: 2015-02-13 More...
 

Journal Announcement: New Impact Factor of 1.643 for Current Oncology!

 

We are pleased to announce to our readers that Current Oncology’s 2013 Impact Factor has increased to 1.643! This is an increase from our 2012 stats, where we received an impact factor of 1.625.

The journal impact factor is a measure of citation frequency that reflects the average number of citations to articles published in science and social science journals. Impact factors are calculated annually for those journals that are indexed in Thomson Reuters Journal Citation Reports. The impact factor of a journal in a given year is the average number of citations a paper published in that journal received during the two previous years. The impact factor is often used to rank the relative importance and scientific caliber of a journal within its field.

Our 2013 Impact Factor is a significant achievement for the journal, and demonstrates the increased recognition of Current Oncology in the field, and the improved relevance and quality of our articles. Thank you to our team of Editors and Section Editors, Reviewers and Authors for their valuable contribution to the journal. We look forward to continued success in 2014 as the journal continues to strengthen and grow!

Multimed Inc.
Publisher of Current Oncology

 
Posted: 2014-07-31 More...
 

GIOTRIF® (afatinib) approved by Health Canada for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation

 

On November 6, 2013, Health Canada approved GIOTRIF® (afatinib) a targeted, oral once-daily tyrosine kinase inhibitor and the first irreversible ErbB Family Blocker approved for the treatment of EGFR mutation positive tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) tablets.

In clinical trials, GIOTRIF® has been shown to offer patients with EGFR mutation positive NSCLC a significant delay in tumour progression,[i] coupled with improvements in their lung cancer related symptoms versus standard chemotherapy.[i]

Dr. Vera Hirsh, GIOTRIF® clinical trial investigator and medical oncologist at Royal Victoria Hospital in Montreal says, “The approval of GIOTRIF® is an exciting advancement because it works differently than other drugs in its class, by irreversibly blocking multiple EGFR pathways involved in tumour growth.”

GIOTRIF®’s unique mode of action enables it to block EGFR (ErbB1) as well as the other relevant members of the ErbB Family. The covalent and, therefore, irreversible binding of GIOTRIF® is unlike other compounds currently on the market which are reversible in that it provides a sustained, selective, and complete ErbB Family Blockade.[i],[ii]

Discovered and developed by Boehringer Ingelheim, GIOTRIF® is the first Health Canada-approved oncology product from the company.

 

References

[i] Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.

[ii]  Reid A, Vidal L, Shaw H, do Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.

 
Posted: 2013-11-25
 

Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award!

 

Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award! Dr. Gold will be awarded the Wilder-Penfield Prize for his work in the ground-breaking discovery of the carcinoembryonic antigen (CEA).

The CEA was discovered in 1965 by Dr. Gold and his colleague, Samuel Freedman. This discovery revolutionized cancer research and is now the most frequently used blood test in modern oncology. The discovery of the CEA also launched the field of oncodevelopmental biology.

Thank you for your important contribution to oncology, Dr. Gold!

 
Posted: 2013-11-20
 

Current Oncology in the News!

 

We are pleased to inform you that an article recently published in Current Oncology has gained much attention throughout Canada.  In the article, the authors discussed the impending implications that HPV and throat cancer will have on healthcare resources.

Click here to read the article “The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population”

A.C. Nichols, D.A. Palma, S.S. Dhaliwal, S. Tan, J. Theuer, W. Chow, C. Rajakumar, S. Um, N. Mundi, S. Berk, R. Zhou, J. Basmaji, G. Rizzo, J.H. Franklin, K. Fung, K. Kwan, B. Wehrli, M.I. Salvadori, E. Winquist, S. Ernst, S. Kuruvilla, N. Read, V. Venkatesan, B. Todorovic, J.A. Hammond, J. Koropatnick, J.S. Mymryk, J. Yoo, J.W. Barrett

Curr Oncol 2013;20:212–9.

(doi: http://dx.doi.org/10.3747/co.20.1375)

The National Post interviewed Dr. David Palma (one of the authors of the article) from the London Regional Cancer Centre.  Click here to read the article.

CTV Toronto later interviewed Dr. Palma live about the implications.  Click here to watch the interview or click on the image below.

 
Posted: 2013-08-14
 

Current Oncology Author Survey Results - Now Available!

 

Author survey results are available now – 89% of respondents highly satisfied or satisfied with overall publishing experience! Further results available at http://mad.ly/3d03c3.

 
Posted: 2013-05-23
 

Current Oncology Author Survey – Winner of iPad mini Announced!

 

Thank you to our contributors who completed our author survey, we truly value your feedback.

All participants who completed the survey were entered into a draw for a chance to win an iPad mini. The winner of the iPad mini is Dr. Tom Oliver. Congratulations!

 
Posted: 2013-05-08
 

Follow @CurrentOncology on Twitter!

 

Current Oncology, Canada’s premier oncology journal, is now on Twitter!

We invite you to connect with us to receive immediate updates regarding the journal, and the latest in Canadian oncology research.

 
Posted: 2013-05-01
 

Current Oncology Readership Survey – Winner of iPad mini Announced!

 

Thank you to our readers who completed our readership survey, we truly value your feedback.

All participants who completed the survey were entered into a draw for a chance to win an iPad mini. The winner of the iPad mini is Dr. Ryna Levy-Milne from British Columbia. Congratulations!

 
Posted: 2013-01-07
 

Impact Factor for Current Oncology increases to 2.473!

 
We are pleased to announce to our readers that Current Oncology’s 2011 Impact Factor has increased to 2.473! We also received a ranking of 103 out of 194 oncology journals. This is a significant increase from our 2010 stats, where we received our first impact factor of 1.820 and ranking of 129 out of 184 journals.
 
 
Posted: 2012-07-04 More...
 

Euthanasia Debate

 

We have all heard much about the controversial topic of euthanasia, especially during the recent months in Canada.

An editorial titled, “Should there be a legal right to die?” by Dr. David Benatar appeared in the December 2010 issue of Current Oncology, which prompted an opinion piece by Dr. José Pereira titled, “Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls” in the April 2011 issue.

These articles ignited a lot of controversy and compelled Current Oncology to develop a series of special articles dedicated to this timely and very much debated topic of euthanasia and assisted suicide for our readership.

These articles, published in the June issue of Current Oncology, are presented for our readers to review and judge for themselves.

Click on the links below to view articles from this special series.

  1. Pereira’s attack on legalizing euthanasia or assisted suicide: smoke and mirrors
  2. Casting stones and casting aspersions: let’s not lose sight of the main issues in the euthanasia debate
  3. Assisted death and the slippery slope—finding clarity amid advocacy, convergence, and complexity

We invite you to join us in the debate on a timely topic relevant to the medical community! Further correspondence is encouraged, and Current Oncology has the ideal forum: the Cancer Knowledge Network, which opinions can be expressed and where dialogue is encouraged.

 
Posted: 2012-06-26
 

The Québec Pancreas Cancer Study (QPCS) is enrolling patients and families affected by pancreatic cancer

 

The QPCS is a clinic-based study with the goal of characterizing the epidemiologic and hereditary factors associated with pancreatic cancer. Biospecimens are also being collected for biomarker, tumour biology, and cancer microenvironment investigations.

All patients with a diagnosis of pancreatic adenocarcinoma are eligible to participate. If there is a family history of pancreatic cancer, relatives of patients with pancreatic cancer may also participate. Patients and their relatives can be referred to the QPCS using our web site (www.cancerpancreas.ca).

Study participants are asked to complete family and personal history questionnaires and to donate a blood or saliva sample. If a participant lives outside the Montreal area or is unable to attend the QPCS research clinic, collection of samples will be done at or close to the participant’s home. Only patients undergoing surgery at the McGill University Health Centre will be asked to donate a small portion of their resection specimen for tumour biology studies.

Each participant will have an opportunity to discuss the study with a QPCS genetic counsellor. The QPCS is affiliated with McGill University, the McGill University Health Centre and the Rosalind and Morris Goodman Cancer Research Centre.  For more information, please see www.cancerpancreas.ca or contact Dr. George Zogopoulos (george.zogopoulos@mcgill.ca).

 
Posted: 2012-04-02 More...
 

Meeting/Conference: Current Oncology Scholars’ Forum & Workshop, May-June 2012, Guangzhou, China

 

Current Oncology Scholars’s Forum & Workshop will be held in May - June 2012, in Guangzhou, China. The forum/workshop welcomes research articles from scientists, doctors and research scholars involved in the area of cancer therapy from all over the world to publish high quality and refereed papers. There will be an issue of Current Oncology publishing accepted papers for this forum/workshop, which are selected through rigorous peer review to ensure originality, timeliness, relevance, and readability. Dr. Qiang Yu, Senior Group Leader, Genome Institute of Singapore, will be the guest editor for this issue. Please follow the relavant link below to format your manuscript http://www.current-oncology.com/index.php/oncology/about/submissions. For paper contribution or other further inquiries, please send email to currentoncology@gmail.com, or current_oncology@hotmail.com.

 
Posted: 2011-10-20
 

Meeting/Conference: Best of Oncology 2011, December 2, Toronto, ON – top advances and clinically relevant updates for 7 tumor sites

 
Registration is now open! http://www.regonline.ca/builder/site/Default.aspx?EventID=954549  
Posted: 2011-09-19 More...
 

Current Oncology welcomes readers and authors from the Chinese Oncology Community

 

We would like to welcome to the Current Oncology team, Dr. Yu (Darwin) Cai as our new Associate Editor in China. Dr. Cai is a Professor from Jinan University, Guangzhou, China.

The journal has partnered with Dr. Cai to encourage more submissions to the journal from Chinese Oncologists, as well as expand our online readership in China.

Dr. Cai’s role is to encourage more submissions to the journal through different academic events including conferences, workshops, and seminars.

Contributions from Chinese authors will help to further increase the international reach and impact of the journal.

We look forward to working with Dr. Cai and welcome submissions from his colleagues.

 
Posted: 2011-08-31
 

New for 2011 – Author Fees

 
As of January 7, 2011, Current Oncology will be implementing Article Processing Fees (APF) and Extra Page Charges (EPC).  
Posted: 2011-01-06 More...
 

Managing Prostate Cancer in 2010 and Beyond: A Canadian Perspective Supplement is Now Available Online!

 

Managing Prostate Cancer in 2010 and Beyond: A Canadian Perspective; a supplement to Current Oncology, is now available online!

 
Posted: 2010-09-15 More...
 

Optimal Management of Metastatic Colorectal Cancer with the Anti-EGFR Monoclonal Antibodies Supplement is Now Available Online!

 

Optimal Management of Metastatic Colorectal Cancer with the Anti-EGFR Monoclonal Antibodies; a supplement to Current Oncology, is now available online!

Coming soon to Current Oncology! A supplemental issue on the management of Prostate Cancer, edited by Dr. Fred Saad.

 
Posted: 2010-06-23 More...
 

Become a Reviewer

 
Register today to become a reviewer for Current Oncology!  
Posted: 2009-06-17 More...
 

Multimed Inc. proud to represent Current Oncology at the 2009 ASCO Annual Meeting!

 

Multimed Inc., publisher of Current Oncology, was pleased to attend the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 to June 2 in Orlando, Florida.

 
Posted: 2009-04-09 More...
 

Integrative Oncology: A Canadian and International Perspective is now available online

 
Integrative Oncology: A Canadian and International Perspective is available online. The supplement to Current Oncology includes papers by selected presenters from the Integrating Wellness into Cancer Care Conference that was held at the University of Toronto on October 4-5th, 2007.  
Posted: 2008-08-27 More...
 

Current Oncology selected for coverage in Thomson Reuters

 
Beginning with 2008 issues, Current Oncology will be indexed and abstracted in the Scientific Citation Index and Journal Citation Reports/Science Edition.  
Posted: 2008-08-21 More...
 

Create a User Account Today!

 
Create a user account on the Current Oncology website to take advantage special benefits only available to registered users.  
Posted: 2008-08-19 More...
 

Current Oncology is Now Included in Pub Med

 
Multimed Inc. is pleased to announce that Current Oncology has been accepted to Pubmed Central.  
Posted: 2008-02-27 More...
 

Current Oncology Has Added a Reprint Page to its Website

 
As Current Oncology is growing in the Canadian and International marketplace, there is an increasing demand for reprints and licensing fees across the globe.  
Posted: 2008-02-27 More...
 

Current Oncology is Now HONCode Accredited

 
Current Oncology has been HONCode accredited as it is in full compliance with HonCode’s 8 principles.  
Posted: 2008-02-27 More...
 

Current Oncology is Now Added to LinkOut

 
Multimed Inc. is pleased to announce that Current Oncology is now a part of LinkOut from PubMed Central! Inclusion by such a high quality archival database helps significantly increase Current Oncology’s visibility.  
Posted: 2007-10-16 More...
 

Current Oncology Has Been Accepted By Journal Selector

 
Multimed Inc. is pleased to announce that Current Oncology has been accepted by Journal Selector.  
Posted: 2007-09-06 More...
 

HINARI

 
Current Oncology is now catalogued in the World Health Organization's HINARI project.  
Posted: 2007-03-27 More...
 

Directory of Open Access Journals

 
Current Oncology has been added to the Directory of Open Access Journals hosted and maintained by Lund University.  
Posted: 2007-02-15 More...
 

Current Oncology Upgrades Website

 
Multimed Inc. is pleased to announce the upgrade of the Current Oncology Website including the newest version of the Public Knowledge Project Open Journal System (PKP).  
Posted: 2007-02-15 More...
 
1 - 40 of 40 Items